References
- Stewart DJ. A Short Primer on Why Cancer Still Sucks. Victoria: Tellwell; 2022.
- Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics 2021. Toronto: Canadian Cancer Society; 2021. Available from: www.cancer.ca/Canadian-Cancer-Statistics-2021-EN. Accessed April 20, 2024.
- Stewart DJ, Stewart AA, Wheatley-Price D, et al. The importance of greater speed in drug development for advanced malignancies. Cancer Med. 2018;7(5):1824–1836. doi:10.1002/cam4.1454
- Gotfrit J, Shin JJW, Mallick R, Stewart DJ, Wheatley-Price P. Potential life-years lost: the impact of the cancer drug regulatory and funding process in Canada. Oncologist. 2020;25(1):e130–7. doi:10.1634/theoncologist.2019-0314
- Longo CJ, Fitch MI, Loree JM, et al. Patient and family financial burden associated with cancer treatment in Canada: a national study. Support Care Cancer. 2021;29(6):3377–3386. doi:10.1007/s00520-020-05907-x
- Vanderpuye-Orgle J, Erim D, Qian Y, et al. Estimating the impact of delayed access to oncology drugs on patient outcomes in Canada. Oncol Ther. 2022;10(1):195–210. doi:10.1007/s40487-022-00187-3
- Garaszczuk R, Yong JHE, Sun Z, de Oliveira C. The economic burden of cancer in Canada from a societal perspective. Curr Oncol. 2022;29(4):2735–2748. doi:10.3390/curroncol29040223
- Powers Smith CE, Prasad V. Targeted cancer therapies. Am Fam Phys. 2021;103(3):155–163.
- Rodak O, Peris-Diaz MD, Olbromski M, et al. Current landscape of non-small cell lung cancer: epidemiology, histological classification, targeted therapies, and immunotherapy. Cancers. 2021;13(18):4705. doi:10.3390/cancers13184705
- Rismanbaf A. Improving targeted small molecule drugs to overcome chemotherapy resistance. Cancer Rep. 2023;7(1):e1945.
- Pigott E, Binder L. Getting better, faster: the case for optimizing access to precision medicines in the wake of the revolution in cancer care. Collective Oncology Network for Exchange, Cancer Care Innovation. Treatment Access & Education; 2023. Available from: https://conected.ca/wp-content/uploads/Getting-Better-Faster-July-5-2023-FINAL-For-Sharing-1.pdf. Accessed April 20, 2024.
- MacPhail C, Snow S. Not all Canadian cancer patients are equal – disparities in public cancer drug funding across Canada. Curr Oncol. 2022;29(3):2064–2072. doi:10.3390/curroncol29030166
- Salek S, Lussier Hoskyn S, Johns JR, Allen N, Sehgal C. Factors influencing delays in patient access to new medicines in Canada: a retrospective study of reimbursement processes in public drug plans. Front Pharmacol. 2019;10:196. doi:10.3389/fphar.2019.00196
- Gotfrit J, Dempster W, Chambers J, Wheatley-Price P. The pathway for new cancer drug access in Canada. Curr Oncol. 2022;29(2):455–464. doi:10.3390/curroncol29020041
- Binder L, Ghadban M, Sit C, Barnard K. Health technology process for oncology drugs: impact of CADTH changes on public payer reimbursement recommendations. Curr Oncol. 2022;29(3):1514–1526. doi:10.3390/curroncol29030127
- Rawson N, Adams J Waiting for new drugs for rare disorders in Canada. Ottawa: Macdonald-Laurier Institute; 2023. Available from: https://macdonaldlaurier.ca/wp-content/uploads/2023/09/20230822_Rare-drugs-RawsonAdams-COMMENTARY-v1-1.pdf. Accessed April 20, 2024.
- Access and time to patient prescription drugs in Canada. Ottawa: Conference Board of Canada; 2024. Available from: https://www.conferenceboard.ca/product/access-and-time-to-patient-jan2024/. Accessed April 20, 2024.
- Glennie J, Gesy K, Nguyen Y Canadian public payer best practices for providing timely patient access to cancer therapies. Can Health Policy; 2023. Available from: 10.54194/VIEL2883. Accessed April 20, 2024.
- Who we are. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2024. Available from: https://www.cadth.ca/who-we-are. Accessed April 20, 2024.
- MacPhail E, Shea B An inside look at the early history of the CADTH Common Drug Review in Canada. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2017. Available from: https://www.cadth.ca/sites/default/files/pdf/early_history_of_CDR.pdf. Accessed April 20, 2024.
- Why CADTH. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2019. Available from: https://www.cadth.ca/why-cadth. Accessed April 20, 2024.
- Financial statements of the Canadian Agency for Drugs and Technologies in Health: year ended March 31, 2023. Ottawa: KPMG; 2023. Available from: https://www.cadth.ca/sites/default/files/pdf/Annual_Report/2023/2023-03-31%20CADTH%20wFS%20ENG%20-%20signed.pdf. Accessed April 20, 2024.
- About pCPA. Toronto: pan-Canadian Pharmaceutical Alliance; 2024. Available from: https://www.pcpacanada.ca/about. Accessed April 20, 2024.
- pCPA Corporation: inaugural report. Toronto: pan-Canadian Pharmaceutical Alliance; 2023. Available from: https://www.pcpacanada.ca/sites/default/files/2023-10/InauguralReport_pCPA_EN_web.pdf. Accessed April 20, 2024.
- Milliken D, Venkatesh J, Yu R, Su Z, Thompson M, Eurich D. Comparison of coverage in Canada before and after the establishment of the pan-Canadian Pharmaceutical Alliance. BMJ Open. 2015;5(9):e008100. doi:10.1136/bmjopen-2015-008100
- Salek SM, Lussier Hoskyn S, Johns J, Allen N, Sehgal C. Pan-Canadian Pharmaceutical Alliance (pCPA): timelines analysis and policy implications. Front Pharmacol. 2019;9:1578. doi:10.3389/fphar.2018.01578
- Procedures for CADTH reimbursement reviews. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2024. Available from: https://www.cadth.ca/sites/default/files/Drug_Review_Process/CADTH%20Drug%20Reimbursement%20Review%20Procedures.pdf. Accessed April 20, 2024.
- pCPA brand process guidelines. Toronto: pan-Canadian Pharmaceutical Alliance; 2023. Available from: https://www.pcpacanada.ca/sites/default/files/eng/pCPA_Brand_Process_Guidelines.pdf. Accessed April 20, 2024.
- Sehdev S, Gotfrit J, Elias M, Stein BD. Impact of systemic delays for patient access to oncology drugs on clinical, economic, and quality of life outcomes in Canada: a call to action. Curr Oncol. 2024;31(3):1460–1469. doi:10.3390/curroncol31030110
- Sehdev S, Rawson NSB, Aseyev OI, et al. Access to oncology medicines in Canada: consensus forum for recommendations for improvement. Curr Oncol. 2024;31(4):1803–1816. doi:10.3390/curroncol31040136
- About us. Toronto: CanCertainty Coalition; 2024. Available from: https://www.cancertaintyforall.ca/about_us. Accessed April 20, 2024.
- Reimbursement review reports. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2024. Available from: https://www.cadth.ca/reimbursement-review-reports. Accessed April 20, 2024.
- Brand name drug negotiations status. Toronto: pan-Canadian Pharmaceutical Alliance; 2024. Available from: https://www.pcpacanada.ca/negotiations. Accessed April 20, 2024.
- Balijepalli C, Gullapalli L, Joshy J, Rawson NSB. The impact of willingness-to-pay threshold on price reduction recommendations for oncology drugs: a review of reimbursement assessments by the Canadian Agency for Drugs and Technologies in Health. J Comp Eff Res. 2024;13(5):e230178. doi:10.57264/cer-2023-0178
- Performance standards for the fees in respect of drugs and medical devices order. Ottawa: Government of Canada; 2024. Available from: https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/performance-fees-drugs-medical-devices.html. Accessed April 20, 2024.
- Fee schedule for CADTH pharmaceutical reviews. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2023. Available from: https://www.cadth.ca/sites/default/files/Drug_Review_Process/CADTH_Application_Fees_pharm.pdf. Accessed April 20, 2024.
- Rawson NSB, Adams J. Do reimbursement recommendation processes used by government drug plans in Canada adhere to good governance principles? Clinicoecon Outcomes Res. 2017;9:721–730. doi:10.2147/CEOR.S144695
- Lin JK, Barnes JI, Doshi JA, et al. Arriving at a fair price in the Medicare drug price negotiation program: considerations from other countries. Health Aff Forefront; 2023. Available from: https://www.healthaffairs.org/do/10.1377/forefront.20231127.569606. Accessed April 20, 2024.
- Rawson NSB, Adams J. Why US Medicare drug price assessments and negotiations should not use Canada as a model. 2024. Available from: https://www.healthaffairs.org/content/forefront/why-us-medicare-drug-price-assessments-and-negotiations-should-not-use-canada-model. Accessed 20 April 2024.
- Stories from the frontlines of the fight for innovative therapies. Toronto: Maclean’s; 2023. Available from: https://macleans.ca/longforms/the-fight-for-access-to-innovative-therapies/. Accessed April 20, 2024.
- Tam VC, Ramjeesingh R, Burkes R, Yoshida EM, Doucette S, Lim HJ. Emerging systemic therapies in advanced unresectable biliary tract cancer: review and Canadian perspective. Curr Oncol. 2022;29(10):7072–7085. doi:10.3390/curroncol29100555
- Li YYR, Mai H, Trudeau ME, et al. Reimbursement recommendations for cancer drugs supported by phase II evidence in Canada. Curr Oncol. 2020;27(5):e495–500. doi:10.3747/co.27.6489
- Dai WF, Craig E, Fraser B, et al. Building a national reassessment process for oncology drugs: lessons learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a simulated exercise. Curr Oncol. 2021;28(6):4645–4654. doi:10.3390/curroncol28060392
- Rawson NSB. Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: who benefits? Orphanet J Rare Dis. 2022;17(1):218. doi:10.1186/s13023-022-02390-x
- Fontrier AM, Kanavos P. Do reimbursement recommendations by the Canadian Agency for Drugs and Technologies in Health translate into coverage decisions for orphan drugs in the Canadian province of Ontario? Value Health. 2023;26(7):1011–1021. doi:10.1016/j.jval.2023.02.013
- Bellehumeur C Increasing access to innovative medicines: pre-budget consultations in advance of the 2023 budget. Ottawa: Innovative Medicines Canada; 2022. Available from: https://innovativemedicines.ca/wp-content/uploads/2022/10/20221007_FINAL_PreBudget_Consultation-1.pdf. Accessed April 20, 2024.
- Berry SR, Evans WK, Strevel EL, Bell CM. Variation and consternation: access to unfunded cancer drugs in Canada. J Oncol Pract. 2012;8(1):35–39. doi:10.1200/JOP.2011.000278